Phase 2 Heart Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with chronic coronary syndrome (a long-term heart condition involving reduced blood flow to the heart)
- People who have at least one artery with a blockage of 50% or more in a vessel that is not the main one being treated, as measured by visual assessment
- People whose chest pain or angina symptoms can be managed with medication
- People whose CT scan of the heart arteries shows a specific characteristic in the fatty tissue surrounding certain arteries (a high "attenuation coefficient" reading of ≥-70.1 HU in the perivascular fat — confirm with trial site if unsure what this means)
- People who are able to attend follow-up appointments and are willing to take prescribed medications as directed
Who may not be able to join:
- People under 18 years of age
- People who are not able to give informed consent, or who are currently enrolled in another clinical trial that has not yet reached its main measurement point
- Women who are pregnant or breastfeeding (a pregnancy test will be required within 7 days before the procedure for women who could potentially become pregnant)
- People who have another medical condition that means their life expectancy is less than 3 years
- People whose heart or circulation is currently unstable
- People who are known to have a medical reason they cannot take the trial drug or its components, heparin, or contrast dye used in scans
- People whose blood or kidney test results at the time of screening fall outside certain thresholds — including measures of liver function, white blood cell counts, platelet levels, and kidney function (confirm specific values with the trial site)
- People who have serious ongoing conditions such as severe systemic illness, cancer, immune system disorders, active infections, or malignancy, where the trial doctor considers participation to be inappropriate
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ling Tao, M.D., Ph.D., Xijing Hospital
Phone: 18629551066
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of high PVAT attenuation coefficient among non-target lesion(s)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.